IGC Pharma, Inc. (IGC)
Oxford Ledge is still expanding full research coverage of IGC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
IGC develops Alzheimer's treatments led by IGC-AD1 in Phase 2 trials, supported by AI-driven drug discovery and a preclinical pipeline.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-07-14
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-07-06
- 8-K Entry into material agreement; Creation of direct financial obligation; Financial statements and exhibits 2026-06-08
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Financial statements and exhibits 2026-04-20
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for IGC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open IGC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.